The Estrogenic Effect of Bisphenol A Disrupts Pancreatic β-Cell Function In Vivo and Induces Insulin Resistance

Paloma Alonso-Magdalena,1 Sumiko Morimoto,1,2 Cristina Ripoll,1 Esther Fuentes,1 and Angel Nadal1

1Instituto de Bioingeniería, Universidad Miguel Hernández de Elche, Alicante, Spain; 2Departamento de Biología de la Reproducción, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” México City, México

Insulin resistance is a crucial constituent of the metabolic syndrome, and its presence predicts type 2 diabetes and atherosclerotic cardiovascular disease (DeFronzo and Ferrannini 1991). In addition to insulin resistance, type 2 diabetes mellitus is also characterized by a progressive β-cell dysfunction. In most patients, both symptoms are present several years before the onset of hyperglycemia.

The incidence of diabetes has increased in the last decades, and at present it is reaching epidemic levels (177 million persons with diabetes in the world; World Health Organization 2005). The cornerstones of its development are related to modern lifestyle, principally, a lack of exercise and an unhealthy diet. Other pathologies whose incidence rose dramatically after World War II, such as cancer, reproductive impairment, and neurodegenerative diseases, are probably related to the increase of endocrine-disrupting chemicals (EDCs) in the environment (Colborn et al. 1996). However, an experimental link between EDCs and diabetes has not yet been established, although a connection at the epidemiologic level in humans has been recently proposed for dioxin, an environmental contaminant that acts through other than estrogen receptors (ERs) as an endocrine disruptor (Bertazzi et al. 2001; Rene and Bunce 2002).

A large number of EDCs act by mimicking the action of the sex hormone 17β-estradiol (E2) (Colborn et al. 1993). In most cases they bind to the classic ERs, ER-α and ER-β (McLachlan 2001; Newbold 2004), but they can also act through novel estrogen targets (Nadal et al. 2005). At physiologic levels, E2 is thought to be involved in maintaining normal insulin sensitivity and to be beneficial for β-cell function (Livingstone and Collison 2002; Louet et al. 2004). However, abnormal levels of E2 may promote insulin resistance (Livingstone and Collison 2002), similar to what occurs in normal puberty and pregnancy (Amiel et al. 1991; Hollingsworth 1983). Therefore, the exposure to an exogenous chemical acting as the natural hormone E2, but at an inappropriate concentration and during an improper time window, may enhance the risk of developing insulin resistance.

In spite of the many clinical studies that link sex steroids and actions of insulin, few studies have investigated the molecular basis of the interaction between E2, the pancreatic β-cell function, blood glucose homeostasis, and the development of diabetes. Pancreatic β-cells contain both types of ERs, ER-α and ER-β (Nadal et al. 2000). Although their functions are still greatly undetermined, ER-α and ER-β are involved in important aspects of the β-cell physiology (Nadal et al. 2004; Sutter-Dub 2002). These include protection against β-cell death caused by cytokines (Contreras et al. 2002) and, after a prolonged application, a beneficial effect on diabetes in mice expressing human islet amyloid peptide (Geisler et al. 2002). The involvement of ERs in lipid and glucose metabolism has been demonstrated in ER-α knockout mice that display increased adiposity, insulin resistance, and glucose intolerance (Heine et al. 2000). In addition, β-cells have the nonclassical membrane ER (ncmER) that triggers rapid effects (Nadal et al. 1998, 2000; Quesada et al. 2002). Recently, a similar receptor has been found in Drosophila (Srivastava et al. 2005). E2 rapidly potentiates β-cell signaling systems and insulin release via this ncmER, an effect that is mimicked by EDCs, including bisphenol A (BPA) (Nadal et al. 2004). BPA is one of the most common chemicals that behaves as an endocrine disruptor. It was the first synthetic estrogen without a steroid structure (Dodds and Lawson 1936), but because of its properties as a cross-linking chemical, BPA was widely chosen by the chemical industry to produce plastic polymers, mainly polycarbonates. Nowadays, it is used in the manufacture of barrier coatings for the inner surfaces of food and beverage cans. High concentrations of BPA have been detected in food and water extracted from autoclaved cans (Brotons et al. 1995). BPA is one of the highest-volume chemicals produced in the world, and its exposure is widespread: it has been found in 95% of the urine samples from people in the United States and to a similar extent is found in human blood, as well (Ikekuzi et al. 2002; vom Saal and Hughes 2005). The European Commission’s Scientific Committee on Food (ECSCF 2002) reported a tolerable daily intake (TDI) of 10 µg/kg/day. However, the U.S. Environmental Protection Agency (U.S. EPA) considers 50 µg/kg/day the reference dose based on the lowest observed adverse effect level (LOAEL) of 50 µg/kg/day, according to studies performed in the 1980s (vom Saal and Hughes 2005). In vivo studies using much lower doses of BPA than the LOAEL have shown that it affects sexual maturation (Howdeshell et al. 1999), induces a decrease in...
daily sperm count and fertility (vom Saal et al. 1998), disrupts chromosome alignment (Hunt et al. 2003), and affects synaptogenesis (McLusky et al. 2005). In spite of this evidence, there is an ongoing debate with the chemical industry that is still skeptical about the risk of low doses of BPA (Bisphenol A Global Industry Group 2005).

In this article we show that the exposure of adult mice to BPA, at doses about 1,000-fold less than the LOAEL established by the U.S. EPA, alters blood glucose homeostasis in vivo. It rapidly increases plasma insulin, altering blood glucose concentration through a nonclassical estrogen pathway. Longer exposure increases β-cell insulin content, an effect that involves classic ERs. These longer exposures generate chronic hyperinsulinemia in the fed state and peripheral insulin resistance.

**Materials and Methods**

**Materials.** We obtained ICI182,780 (ICI) from Tocris Cookson Ltd. (Avonmouth, UK), tocopherol-stripped corn oil from MP Biomedicals, LLC (Solon, OH, USA), and soluble insulin from Humulina Regular (Lilly, Madrid, Spain). Other substances were obtained from Sigma (Madrid, Spain).

**Animals.** We used Swiss albino OF1 male mice (8–10 weeks of age) throughout this study. All animals were kept under standard housing conditions and were treated humanely and with regard for alleviation of suffering. An internal animal care and use committee reviewed and approved the method used.

**Treatment.** Stimuli (E2 and BPA) were dissolved in tocopherol-stripped corn oil and administered subcutaneously at various concentrations. The amount of vehicle was kept constant at 100 μL. In long-term experiments, animals were injected twice per day, at 0900 hr and 2000 hr, with 50 μg/kg or 5 μg/kg of test compound. Two injections of 50 μg/kg/day during 4 days gave a plasma concentration of E2 similar to that found in late pregnancy (Song et al. 2001). In ICI experiments, animals were injected intraperitoneally with a single dose of 500 μg/kg/day for 3–4 days, always at 0800 hr.

**Glycemia determination.** We determined glucose in blood obtained from the tail vein using an Accu-check compact glucometer (Roche Diagnostic GmbH, Mannheim, Germany).

**Insulin secretion and content.** To measure insulin release from isolated islets, mice were killed by cervical dislocation, and pancreatic islets of Langerhans were isolated by collagenase digestion as described previously (Morimoto et al. 2001). Islets were washed twice with a buffer solution containing 20 mM HEPES, 115 mM NaCl, 5 mM NaHCO3, 5 mM KCl, 2.6 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 3 mM D-glucose, and 1% bovine serum albumin (pH 7.4). Groups of 10 islets were then incubated in 1 mL of this buffer in the presence of 3,7, and 16 mM glucose. After 1 hr, the medium was collected, and insulin was measured in duplicate samples by radioimmunooassay using a Coat-a-Count kit (DPC, Los Angeles, CA, USA). The insulin content was determined in islets isolated as described above. Islets were grouped in batches of 10 and incubated overnight in an ethanol/HCl buffer at 4°C. At the end of the incubation period, the buffer was removed and studied for insulin content using radioimmunooassay with a Coat-a-Count kit (DPC). Protein determination was performed by the Bradford dye method.

**Immunocytochemistry and insulin content.** Islets isolated as above were dispersed into single cells as previously described (Nadal et al. 1998). Briefly, islets were disaggregated into single cells with trypsin. Cells were then centrifuged and resuspended in Hank’s modified medium supplemented with 200 U/mL penicillin, 0.2 mg/mL streptomycin, 5 mM glucose, and 1% fatty acid–free albumin, pH 7.4. They were then plated on 24-well tissue culture plates. After 30 min, cells were washed with phosphate-buffered saline (PBS) and fixed with Bouin’s solution for 5 min. Then, they were dehydrated with 30, 50, and 70% ethanol, 3 min each, and then washed with PBS. After washing, these cells were first incubated with a monoclonal anti-insulin antibody (1:200 dilution; Sigma, Madrid, Spain) for 2 hr and then for 1 hr with a secondary antibody, anti-mouse IgG-conjugated fluorescein isothiocyanate (IgG-FITC; 1:200 dilution; Sigma, Madrid, Spain) for 2 hr and then for 1 hr with a secondary antibody, anti-mouse IgG-conjugated fluorescein isothiocyanate (IgG-FITC; 1:200 dilution; Sigma, Madrid, Spain) for 2 hr and then for 1 hr with a secondary antibody, anti-mouse IgG-conjugated fluorescein isothiocyanate (IgG-FITC; 1:200 dilution; Sigma, Madrid, Spain). Both at room temperature. Cells were washed with PBS overnight. Images were acquired with a confocal microscope Zeiss Pascal 5 using a Zeiss 20× objective (numerical aperture = 0.5) and analyzed using LSM Zeiss software (Zeiss, Jena, Germany). We measured immunofluorescence intensity in random fields. The results were expressed as average pixel intensity of vehicle-treated animals at the corresponding days.

**Glucose and insulin tolerance tests.** For glucose tolerance tests, animals were fasted overnight for 12 hr, and blood samples were obtained from the tail vein. Animals were then injected intraperitoneally with 2 g/kg body weight of glucose, and blood samples were taken at the indicated intervals.

For insulin tolerance tests, fed animals were used. Animals were injected intraperitoneally with 0.75 IU/kg body weight of soluble insulin. Blood glucose was measured in each sample using an Accu-check compact glucometer (Roche).

**Statistical analysis.** Data are expressed as mean ± SE. Pairwise comparisons were made using Student’s t-test. A probability level < 0.05 was considered statistically significant.

**Results**

**E2 and BPA rapidly alter glycemia and insulinemia.** In vitro, both E2 and BPA alter the function of pancreatic β-cells through the ncmER (Nadal et al. 1998, 2000; Quesada et al. 2002; Ropero et al. 2002). In vivo, the administration of 10 μg/kg E2 to adult male mice resulted in a significant decrease of glycemia measured at 30, 60, and 120 min after the injection, compared to the increase of blood glucose produced by the fatty acids contained in the vehicle injection (tocopherol-stripped corn oil) (Figure 1A). The administration of 1, 10, and 100 μg/kg E2 evoked a clear dose-dependent decrease in the rise of glycemia 30 min after the E2 injection (Figure 1B). This effect is mimicked by equal doses of the environmental estrogen BPA (Figure 1C). Thirty minutes after injection, this decrease in blood glucose is parallel to an increase in plasma insulin (Figure 1D) of 3.20 ± 0.45-fold for E2-treated mice and 2.76 ± 0.5-fold for BPA-treated mice. Rapid effects elicited by E2 and BPA in islets of Langerhans in vivo are initiated after they bind at the ncmER that is insensitive to the pure antiestrogen ICI (Nadal et al. 2004). This antiestrogen was described as blocking classic ER-mediated actions in vivo (Johnson et al. 2003; Perez-Martin et al. 2003). To evaluate whether the E2 and BPA actions described above require an ER with a sensitivity to the pure antiestrogen similar to a classical ER, we undertook experiments using mice treated with 500 μg/kg/day ICI administered intraperitoneally for 3 days (Johnson et al. 2003). As shown in Figure 2A, ICI had no effect on the E2 and BPA-dependent blood glucose decrease nor on the E2- and BPA-dependent increase of plasma insulin (Figure 2B).

Therefore, both E2 and BPA rapidly change glycemia most likely by inducing an hypersecretion of insulin through a nonclassical ER-mediated mechanism that may involve the ncmER previously described in these cells (Nadal et al. 2000, 2004).
Afterward, insulin content was measured in individual cells by immunocytochemistry. Figure 3A shows confocal images of β-cells obtained from mice treated 4 days with vehicle, 100 µg/kg/day E2, or 100 µg/kg/day BPA. Figure 3B illustrates a three-dimensional reconstruction of images in Figure 3A showing a pixel intensity scale from 0 to 256 pixels. The images and the three-dimensional graphs illustrate that β-cells from animals treated with E2 and BPA presented higher staining than those treated with the vehicle and thus higher insulin content in every cell. After 4 days of treatment, the insulin increase was already manifested at doses of 10 µg/kg/day of either E2 or BPA (Figure 3C). Nonetheless, this effect was small and 100 µg/kg/day was needed to produce a potent increase in insulin content (Figure 3C). A treatment of 100 µg/kg/day E2 for 4 days gives an E2 plasma concentration similar to that found in late pregnancy (Song et al. 2001). Therefore, the chronic action of E2 and BPA was manifested at higher concentrations than was required for the acute effect. On the basis of this response, we use 100 µg/kg/day as the paradigmatic concentration in long-term experiments.

Time-course experiments demonstrated that the onset of the increase in insulin content occurs after 24–48 hr of treatment with either E2 or BPA (Figure 3D). The experiment in Figure 3D shows that most single β-cells increased their insulin content. The experiment in Figure 3D shows that after 4 days of treatment, the insulin content is higher in E2 and BPA-treated mice. The radioimmunoassay analysis of insulin content performed 4 days after the treatment with 100 µg/kg/day of either E2 or BPA produced similar results as those presented with immunocytochemistry (Figure 3E). These results demonstrate that the insulin content was increased by both the natural hormone and the environmental estrogen to a similar extent.

To study the involvement of classical ERs in the regulation of E2- and BPA-induced insulin expression, we used mice treated with the antiestrogen ICI, as described for the experiment presented in Figure 2. Animals treated with 100 µg/kg/day E2 for 4 days presented higher levels of insulin immunoreactivity than the control (Figure 4A). In animals treated with ICI, E2 had no effect (Figure 4A). The action of the pure antiestrogen is manifested to the same extent with BPA, as demonstrated by immunocytochemistry (Figure 4B) and radioimmunoassay (Figure 4C). The ability of the pure antiestrogen to completely block the effect of both E2 and BPA indicates that the action performed on insulin content is mediated by a classical ER.

**E2 and BPA administration provokes hyperinsulinemia and insulin resistance.** An increment in the insulin content of every β-cell within an islet causes it to release a higher amount of insulin every time it is stimulated (Marban et al. 1989). This occurs, for instance, during pregnancy, when islets adapt to deal with peripheral insulin resistance (Costrini and Kalkhoff 1971; Faure et al. 1985). In our system (Figure 5A), we show that, at high glucose concentrations (16 mM), islets from mice treated with 100 µg/kg/day E2 for 4 days secrete 1.54 ± 0.12-fold more insulin than those from mice treated with the vehicle, and the same occurs in islets from mice treated
with BPA. In the latter case, differences are significant even at lower glucose concentrations (7 mM). This effect has been recently described in vitro (Adachi et al. 2005). Therefore, if E2- and BPA-treated mice have higher insulin content, they should release more insulin than untreated mice, and accordingly, these animals should be hypoinulinemic in the fed state. This is shown in Figure 5B: 4 days after the E2 treatment, fed mice had blood insulin levels 1.7-fold higher than those of vehicle-treated mice. Blood glucose levels were 186 ± 5 mg/dL in vehicle-treated mice and 170 ± 6 mg/dL in E2-treated mice (p = 0.065, not significant). Plasma insulin levels for the group treated with BPA were 1.5-fold higher than those for the vehicle-treated mice; however, their blood glucose levels were 153 ± 4 mg/dL for the vehicle (n = 5) and 154 ± 7 mg/dL for BPA (n = 7; p = 0.93). This experiment indicates that, in the E2-treated animals, there was mild insulin resistance, because there are 1.7-fold higher circulating insulin levels but a decrease of blood glucose, although it is not significant.

This effect is remarkably manifested with BPA; in this case, plasma insulin levels are 1.53-fold higher and blood glucose concentration does not vary, a clear symptom of insulin resistance.

To prove that glucose tolerance is altered, we performed an intraperitoneal glucose tolerance test in fasted (12 hr) mice. Contrary to vehicle-treated mice, blood glucose increased to a higher level in E2-treated (Figure 6A) and BPA-treated mice (Figure 6B). The higher increase in blood glucose manifested 15 and 30 min after a glucose challenge. We found that the area under the curve (milligrams per deciliter-minute) was 162 ± 6 (vehicle, n = 24), 181 ± 5 (E2, n = 16, p = 0.025 vs. vehicle), and 190 ± 8 (BPA, n = 8, p = 0.028 vs. vehicle). These results indicate that an impaired glucose tolerance was present in E2-treated mice and in those treated with BPA. When an insulin tolerance test (intraperitoneal injection of 0.75 IU/kg body weight soluble insulin) was performed in fed mice, a significantly reduced hypoglycemic response was observed in both E2- and BPA-treated mice (Figure 6C). This insulin intolerance also manifested in animals given an oral dose of 100 µg/kg/day BPA for 4 days. In this case, the BPA was dissolved in tocopherol-stripped corn oil and delivered through a pipette placed into the animal’s mouth (Howdeshell et al. 1999) (Figure 6D). All these results indicate that E2-treated animals and, in a remarkably similar manner, BPA-treated animals develop insulin resistance without any changes in glyceria or weight (35–40 g, with no significant differences between the diverse treatments applied).

Figure 3. Insulin content in β-cells from E2- and BPA-treated mice. (A) Immunofluorescent staining of insulin in cells from mice treated with vehicle, 100 µg/kg/day E2, or 100 µg/kg/day BPA for 4 days. Bar = 50 µm; blue indicates low fluorescence intensity, and red indicates high intensity. (B) Three-dimensional graphs of cells in (A), showing the pixel intensity [0 (low) to 256 pixels (high)]. (C) Quantification of insulin content using confocal microscopy of β-cells from mice treated with vehicle, E2, or BPA for 4 days at either 10 or 100 µg/kg/day, shown as normalized pixel intensity. Each point represents the mean of at least 1,000 cells from three mice; *p < 0.003 compared with vehicle. (D) Time course indicating E2 and BPA action in β-cells. Each point represents the mean of at least 1,000 single cells obtained from two mice; **p < 10−5 compared with vehicle. (E) Insulin content of islets obtained from mice treated with vehicle, 100 µg/kg/day E2 (n = 6; *p = 0.014), or 100 µg/kg/day BPA for 4 days (n = 6; **p = 0.04). All error bars indicate SE.
Discussion

The results presented in this article demonstrate a link between estrogenic endocrine disruptors and insulin resistance. We have shown that BPA mimics E2 effects on blood glucose homeostasis through two different pathways. A nonclassical pathway produces a rapid increase in plasma insulin and a decrease in blood glucose. This is unaffected by the antiestrogen ICI and is most likely initiated by the ncmER already described in islet cells (Alonso-Magdalena et al. 2005; Nadal et al. 2000; Quesada et al. 2002; Ropero et al. 2002). Nonetheless, other estrogen and xenoestrogen actions initiated at the plasma membrane are mediated via classical ERs (Losel et al. 2003; Wozniak et al. 2005). The activation of this alternative pathway occurs at low doses of both E2 and BPA, becoming significant at 10 µg/kg. When animals were treated with either the natural hormone or BPA for a longer period of time, there was an increase in the pancreatic insulin content. This effect was completely blocked by ICI, suggesting that a classical ER is involved. This implies that the action described here for E2 and BPA can be extrapolated to other estrogenic EDCs. Any EDC having an estrogenic effect through classical ERs can be a candidate to induce insulin overexpression. This chronic treatment induced insulin resistance.

Type 2 diabetes mellitus is characterized by insulin resistance, which results in lower levels of blood glucose uptake into target tissues. Consequently, blood glucose levels increase and more insulin is released, producing hyperinsulinemia, which manifests early in type 2 diabetes. In addition, several studies have demonstrated that the hypersecretion of insulin is a primary defect of type 2 diabetes and that insulin resistance develops secondarily to the chronic hyperinsulinemia (Charollais et al. 2000; DeFronzo 1997; Devedjian et al. 2000; McGurry 1992). Indeed, the persistence of chronic physiologic euglycemic hyperinsulinemia for 3–5 days can induce severe insulin resistance in healthy subjects with normal glucose tolerance (Del Prato et al. 1994). Furthermore, patients with insulinoma display a correlation between hyperinsulinemia and insulin resistance (Pontiroli et al. 1992; Skrha et al. 1996). When insulin is overexpressed, a chronic hyperinsulinemia manifests, as shown in transgenic mice that overexpress the insulin gene (Marban et al. 1989). Remarkably, these transgenic mice developed insulin resistance. Here we have shown that 4 days of treatment with either E2 or BPA induces an increase in β-cell insulin content; these mice were hyperinsulinemic and presented altered glucose and insulin tolerance tests. These alterations may result from a direct effect of E2 and BPA on β-cell insulin content, or a compensatory response resulting from the insulin resistance noted in these animals, or both.

We have demonstrated that after 4 days of treatment, isolated islets respond more vigorously to glucose (Figure 5A), likely because their insulin content is higher (Marban et al. 1989). This phenomenon may be responsible for the chronic hyperinsulinemia that manifested in the fed state (Figure 5B). In addition, the altered glucose and insulin tolerance test results were consistent with the fact that these mice had developed insulin resistance. Therefore, our results suggest that the sustained hyperinsulinemia produced by E2 and BPA...
Bisphenol A induces insulin resistance

The results presented here show a rapid nongenomic effect at a dose of 10 µg/kg/day, five times lower than the reference dose established by the U.S. EPA and equal to the TDI reported by the ECSCF. This dose of BPA results in levels of parent (unconjugated) BPA in blood of 3–4 nM after 30 min and maintained 24 hr later (Zalko et al. 2003), below the level reported in blood from human fetuses at parturition (Schonfelder et al. 2002). This low dose of BPA produces a 2.5-fold increase in plasma insulin and a 20% decrease in blood glucose levels, 30 min after its application. Remarkably, a low dose of 10 µg/kg/day was able to slightly change insulin content as well. A higher dose of 100 µg/kg/day dramatically increased pancreatic insulin content after only 4 days of exposure. Moreover, this treatment, delivering BPA either via injection or through oral intake, induced insulin resistance. This dose is only twice the reference dose recommended by the U.S. EPA and 10 times higher than the TDI recommended by the ECSCF.

The present study demonstrates a connection between BPA and insulin resistance at doses much lower than the LOAEL used up to now (50 mg/kg/day), and therefore it is strong evidence supporting a review of the risk assessment concerning BPA.

Figure 6. E2 and BPA alter glucose tolerance and induce insulin resistance. (A) Glucose tolerance test in mice treated with vehicle or 100 µg/kg/day E2 for 4 days; (n = 16); *p = 0.02, and **p = 0.003. (B) Same experiment as in (A) but with animals treated with vehicle or 100 µg/kg/day BPA (n = 8); *p = 0.017, and **p = 0.009. (C) Insulin tolerance test in awake, fed mice previously treated with vehicle, 100 µg/kg/day E2, or 100 µg/kg/day BPA (n = 9); *p = 0.04, **p = 0.007, and ***p = 0.0002 compared with vehicle. (D) Experiment as in (C) but using an oral intake of either vehicle or 100 µg/kg/day BPA (n = 5); *p = 0.026, and **p = 0.0012. All error bars indicate SE.

REFERENCES

Adachi T, Yasuda K, Mori C, Yoshinaga M, Aoki N, Tsujimoto G. 2005. Promoting insulin secretion from pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors. Food Chem Toxicol 43:713–719.

Alonso-Magdalena P, Laribi O, Ropero AB, Fuentes E, Ripoll C, Soria B, et al. 2005. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic ß-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect 113:968–977; doi:10.1289/ehp.8002 [Online 18 May 2005].

Amiel SA, Caprio S, Sherwin RS, Plevge W, Hammond MW, Tamborlane WV. 1991. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 72:277–282.

Bertazzi PA, Consonni D, Bachietti S, Rubagotti M, Baccarelli A, Zacchetti C, et al. 2001. Health effects of dioxin exposure: a 20-year mortality study. Am J Epidemiol 153:1031–1044.

Bisphenol A Global Industry Group. 2005. Bisphenol A Homepage. Arlington VA:Bisphenol A Global Industry Group of the American Plastics Council. Available: http://www.bisphenol-a.org/ [accessed 31 August 2005].

Brotos JA, Olie-Serrano MF, Vilarobos M, Pedraza V, Olie N. 1995. Xenoestrogens released from lacquer coatings in food cans. Environ Health Perspect 103:608–612.

Charalais A, Ginoir B, Huarte J, Bausaux J, Nadal A, Martin F, et al. 2005. Junctional communication of pancreatic beta cells contributes to the control of insulin secretion and glucose tolerance. J Clin Invest 106:235–243.

Colborn T, Myers JP, Dunowsky O. 1996. Our Stolen Future. New York:Dutton.

Colborn T, vom Saal FS, Soto AM. 1993. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 101:378–384.

Contreras JL, Smyth CA, Bilbao G, Young CJ, Thompson JA, Eckhoff DE. 2002. 17ß-Estradiol protects isolated human pancreatic islets against proinflammatory cytokine-induced cell death: molecular mechanisms and islet functionally. Transplantation 74:1252–1259.

Costini NV, Kalkhoff RK. 1971. Relative effects of estrogen, estradiol, and progesterone on plasma insulin and pancreatic islet insulin secretion. J Clin Invest 50:992–999.

DeFranzo RA, Ferrannini E. 1991. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hyper-tension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–94.

Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. 1995. Xenoestrogens released from lacquer coatings in food cans. Environ Health Perspect 103:608–612.

Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. 1994. Effect of sustained physiologic hyper-insulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37:1025–1035.

Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pulegín M, et al. 2000. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. J Clin Invest 105:731–740.

Dodd EC, Lawson W. 1936. Synthetic oestrogenic agents without the phænotropin nucleus. Nature 137:996.

ECSCF. 2002. Opinion of the Scientific Committee on Food on Bisphenol A. SCF/CSF/P/3936 Final. Brussels:European Commission Scientific Committee on Food. Available: http://ec.europa.eu/comm/food/fs/sc/scf/out129_en.pdf [accessed 31 August 2005].

Faure A, Hauwari M, Sutter BC. 1985. Insulin secretion and biosynthesis after oestrogen treatment. Horm Metab Res 17:378.

Geisler JG, Zawalich W, Zawalich K, Laskey JR, Stukenbrok H, Milici AJ, et al. 2002. Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. Diabetes 51:2180–2186.

Heinl JI. 2003. Endocrine disruptors and the obesity epidemic. Toxicol Sci 76:247–249.

Heine PA, Taylor JA, Ivamoto GA, Lubahn DB, Cooke PS. 2000. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 97:12729–12734.

Hollingsworth DR. 1992. Alterations of maternal metabolism in normal and diabetic pregnancies: differences in insulin-dependent, non-insulin-dependent, and gestational diabetes. Am J Obstet Gynecol 146:417–429.

Howdeshell KL, Hotchkiss AK, Thayer KA, Vandenbergh JG,

Bisphenol A induces insulin resistance

affects peripheral tissues, producing insulin resistance, most likely by down-regulation of insulin receptor number and function. However, the extent of the insulin resistance with this treatment is not enough to induce hyperglycemia in the fasted state.

The assumption described above does not rule out a direct effect of both E2 and BPA on peripheral tissue. BPA produces down-regulation of glucose transporters in adipocytes (Sakurai et al. 2004), an action that may induce insulin resistance. Moreover, BPA combined with insulin favors the conversion of fibroblasts to adipocytes (Masuno et al. 2004), enhancing the risk of obesity, a metabolic disorder that has been related to endocrine disruptors in the last years (Heinl 2003; Mead 2004). Hence, the direct effect of BPA on peripheral tissue might also be of importance to developing insulin resistance.

At present, there is a debate about determining the safe levels of BPA exposure and whether there is a need for a new risk assessment (vom Saal and Hughes 2005). The U.S. EPA considers 50 µg/kg/day as the reference dose based on a LOAEL of 50 mg/kg/day, according to studies performed in the 1980s (vom Saal and Hughes 2005). The ECSCF (2002) reported a TDI of 10 µg/kg/day. The
vom Saal FS. 1999. Exposure to bisphenol A advances puberty. Nature 401:763–764.

Hunt PA, Koehler KE, Susiano M, O’Dowd CA, Llanas A, Voigt RC, et al. 2003. Bisphenol A exposure causes meiotic aneu-
plody in the female mouse. Curr Biol 13:546–553.

Ikezuki Y, Tsumura O, Takai Y, Kamei Y, Taketani Y. 2002. Determination of bisphenol A concentrations in human bi-
ological fluids reveals significant early prenatal exposure. Hum Reprod 17:2839–2841.

Johnson MD, Kenney N, Stoica A, Hilakivi-Clarke L, Singh B, Chepko G, et al. 2002. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nat Med 9:1081–1084.

Livingstone C, Collison M. 2002. Sex steroids and insulin resis-
tance. Clin Sci 102:151–166.

Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Roosol-Haseroth K, et al. 2003. Nongenomic steroid action: 
controversies, questions, and answers. Physiol Rev 83:965–1016.

Louet JF, LeMay C, Mauvais-Jarvis F. 2004. Antidiabetic actions of 
estrogen: insights from humans and genetic mouse models. Curr Atheroscler Rep 6:180–185.

Marban SL, DeLoia JA, Gearhart JD. 1989. Hyperinsulinemia in 
transgenic mice carrying multiple copies of the human 
insulin gene. Dev Genet 10:355–364.

Masuno H, Kidani T, Sekiya K, Shiosaka T, Yamamoto H. 2002. Bisphenol A in combination with insulin can 
accelerate the conversion of 3T3-L1 fibroblasts to 
adipocytes. J Lipid Res 43:676–684.

McGurry JD. 1992. What if Minkowski had been ageusic? An 
unpublished keynote lecture presented at the 4th 
International Congress of the European Academy of 
Neuroendocrinology, Athens, Greece.

McGurry JD. 2001. Environmental signaling: what embryos and 
endoderm can tell us about endocrine disrupting chemicals. 
Environ Health Perspect 113:926–933; doi:10.1289/ehp.7713 [Online 13 April 2005]

McGurry JD. 2002. Rapid, nongenomic responses to ecdysteroids 
and catecholamines mediated by a novel drosophila 
plasma membrane receptor. J Neurosci 22:859–868.

Mead MN. 2004. Origins of obesity. Environ Health Perspect 112:434.

Morimoto S, Fernandez-Mejia C, Romero-Navarro G, Morales-
Peza N, Diaz-Sanchez V. 2001. Testosterone effect on insulin 
content, messenger ribonucleic acid levels, promoter activ-
ity, and secretion in the rat. Endocrinology 142:1442–1447.

Nadal A, Alonso-Magdalena P, Ripoll E, Fuentes E. 2005. 
Disentangling the molecular mechanism of action of natural 
and environmental estrogens. Pflugers Arch 459:335–343.

Nadal A, Ropero AB, Fuentes E, Soria B, Ripoll C. 2004. Estrogen 
and xenestrogens actions on endothelial pancreas: from ion 
channel modulation to activation of nuclear function. 
Steroids 69:531–536.

Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E, Soria B. 
2000. Nongenomic actions of estrogens and xenostrogens 
by binding at a plasma membrane receptor unrelated to 
estrogen receptor alpha and estrogen receptor beta. Proc 
Natl Acad Sci USA 97:11603–11608.

Nadal A, Rovira JM, Laribi O, Leon-Quinte T, Andreu E, Ripoll C, et al. 1998. Rapid insulinotropic effect of 17beta-estradiol 
via a plasma membrane receptor. FASEB J 12:1314–1348.

Nebold RR. 2004. Lessons learned from perinatal exposure to 
diethylstilbestrol. Toxicol Appl Pharmacol 198:142–150.

Perez-Martín M, Azcutia I, Trejo JL, Sierra A, Garcia-Segura LM. 2003. An antagonist of estrogen receptors blocks the 
induction of adult neurogenesis by insulin-like growth fac-
tor-I in the dentate gyrus of adult female rat. European J 
Neurosci 18:923–930.

Pontiroli AE, Alberetto M, Pozza G. 1992. Patients with insuli-
noma show insulin resistance in the absence of arterial 
hypertension. Diabetologia 35:294–295.

Quesada I, Fuentes E, Viso-Leon MC, Soria B, Ripoll C, Nadal A. 
2002. Low doses of the endocrine disruptor bisphenol-A 
and the native hormone 17beta-estradiol rapidly activate 
transcription factor CREB. FASEB J 16:1671–1673.

Remillard RRJ, Bunce NJ. 2002. Linking dioxins to diabetes: epi-
demiology and biologic plausibility. Environ Health Perspect 110:855–856.

Ropero AB, Soria B, Nadal A. 2002. A nonclassical estrogen 
membrane receptor triggers rapid differential actions in 
the endothelial pancreas. Mol Endocrinol 16:497–505.

Sakurai K, Kawazuma M, Adachi T, Harigaya T, Saito Y, Hashimoto N, et al. 2004. Bisphenol A affects glucose 
transport in mouse 3T3-F442A adipocytes. Br J Pharmacol 
141:209–214.

Schonfelder G, Wittfahr W, Hopp H, Taislens CE, Paul M, 
Chahoud I. 2002. Parent bisphenol A accumulation in the 
human maternal-fetal-placental unit. Environ Health Perspect 110:A703–A707.

Skrha J, Sindelka G, Haas T, Hilgertova J, Justova V. 1996. 
Comparison of insulin sensitivity in patients with insulinoma 
and obese type 2 diabetes mellitus. Horm Metab Res 
28:595–598.

Song M, Helguera G, Eghbali M, Zhu N, Zarei MM, Olcese R, 
et al. 2001. Remodeling of Kv4.3 potassium channel gene 
expression under the control of sex hormones. J Biol Chem 276:31883–31890.

Srivastava DP, Yu LJ, Kennedy K, Chatwin H, Reale V, Hamon M, 
et al. 2005. Rapid, nongenomic responses to ecycosteroids 
and catecholamines mediated by a novel drosophila 
G-protein-coupled receptor. J Neurosci 25:6145–6155.

Sutter-Dub MT. 2002. Rapid non-genomic and genomic 
responses to progesterogens, estrogens, and glucocorticoids 
in the endocrine pancreatic B cell, the adipocyte and other 
cell types. Steroids 67:77–83.

vom Saal FS, Cooke FS, Buchanan DL, Palanza P, Thayer KA, 
Nagel SC, et al. 1998. A physiologically based approach to the 
study of bisphenol A and other estrogenic chemicals 
on the size of reproductive organs, daily sperm production 
and behavior. Toxicol Ind Health 14:239–260.

Wozniak AL, Bulayeva NN, Watson CS. 2005. Bisphenol-A at 
low doses: a novel mechanism of action. Environ Health Perspect 
113:926–933; doi:10.1289/ehp.7505 [Online 13 April 2005]

World Health Organization. 2005. Welcome to the Diabetes 
Program. Available: http://www.who.int/diabetes/en/ 
[accessed 23 November 2005].

Wozniak AL, Bulayeva NN, Watson CS. 2005. Bisphenol-A at 
low doses: a novel mechanism of action. Environ Health Perspect 
113:926–933; doi:10.1289/ehp.7505 [Online 13 April 2005]

Zelko D, Sato AM, Dolo L, Dorio C, Rathahao E, Debrauwer L, 
et al. 2003. Nongenomic and genomic response to bisphenol A in 
a mammalian model: answers and new questions raised by low- 
dose metabolic fate studies in pregnant CD1 mice. Environ 
Health Perspect 111:309–319.